Amendments to the Specification:

Please replace the paragraph beginning on page 64, line 33, with the following rewritten paragraph:

--Pharmacologically, α_2-adrenergic receptors are defined as highly sensitive to the antagonists yohimbine (Ki= 0.5-25 ~~μ~~nM), atipamezole (Ki=0.5-2.5 ~~μ~~nM), and idazoxan (Ki=21-35 M) and with low sensitivity to the α_1 receptor antagonist prazosin. Agonists selective for the α_2-adrenergic receptor class relative to the α_1-adrenergic receptor class are UK14304, BHT920 and BHT933. Oxymetazoline binds with high affinity and selectivity to the α_{2A}-receptor subtype (K_D=3~~μ~~nM), but in addition binds with high affinity to α_1-adrenergic receptors and 5HT1 receptors. An additional complicating factor is that α_2-adrenergic receptor ligands which are imidazolines (clonidine, idazoxan) and others (oxymetazoline and UK14304) also bind with high affinity (namomolar) to non-adrenoceptor imidazoline binding sites. Furthermore, species variation in the pharmacology of the α_{2A}-adrenoceptor exists. To date, subtype-selective α_2-adrenergic receptor ligands show only minimal selectivity or are nonselective with respect to other specific receptors, such that the therapeutic properties of subtype selective drugs are still under development.--

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688